Overview
Advanced Medical Solutions Group (AMS) is a world-leading independent developer and manufacturer of innovative tissue-healing technology, focused on value for its customers and quality outcomes for patients. AMS has a wide range of surgical products including tissue adhesives, sutures, haemostatic devices, internal fixation devices, and internal sealants, which it markets under its brands LiquiBand, RESORBA, LiquiBandFix8, LIQUIFIX, and Seal-G. AMS
...
Read More also supplies wound care dressings such as silver alginates, alginates, and foams through its ActivHeal brand as well as under white label. The company has R&D innovation hubs in the UK, Ireland, Germany, France, and Israel. Established in 1991, AMS operates through two business units – Surgical and Woundcare. The US generates majority of its revenue.
Read Less
Read More also supplies wound care dressings such as silver alginates, alginates, and foams through its ActivHeal brand as well as under white label. The company has R&D innovation hubs in the UK, Ireland, Germany, France, and Israel. Established in 1991, AMS operates through two business units – Surgical and Woundcare. The US generates majority of its revenue.
Read Less
Edward Johnson
See more contacts
Management of Companies and Enterprises
,
Resin, Synthetic Rubber, and Artificial and Synthetic Fibers and Filaments Manufacturing
,
Holding companies, nec
,
Synthetic rubber
?
$159.99 million
Actual
1.51%
-22.14%
$289
DEC
?
?
London SETS:AMS
Contacts
Get in Touch with 6 Principals* and 4 Contacts
-
Edward JohnsonDirector
-
Contact 2?
-
Contact 3?
-
Contact 4?
Dynamic search and list-building capabilities
Real-time trigger alerts
Comprehensive company profiles
Valuable research and technology reports
Financial Statements
Dun & Bradstreet collects private company financials for more than 23 million companies worldwide. Find out more.
Financial data as of December 31, 2024 (12 month period) in USD
Annual Revenue 2023
$159.99 million
USD
Actual
1 USD = 0.7888 GBP
All financial statement data is in millions except per share data | Source: Morningstar
| Cash Flow (mil) | 2023 | 2022 | 2021 |
|---|---|---|---|
| Net Operating Cash | $16 | $34 | $39 |
| Net Investing Cash | -$26 | -$15 | -$8 |
| Net Financing Cash | -$17 | -$8 | -$6 |
| Net Change in Cash | -$27 | $11 | $25 |
| Cash at Beginning of Period | $104 | $92 | $68 |
| Cash at End of Period | $76 | $104 | $92 |
| Capital Expenditure | -$12 | -$13 | -$8 |
| Assets (mil) | 2023 | 2022 | 2021 |
|---|---|---|---|
| Current Assets | |||
| Cash and Cash Equivalents | $76 | $104 | $92 |
| Accounts Receivable | $27 | $22 | $22 |
| Inventories | $46 | $35 | $24 |
| Other Current Assets | $7 | $5 | $7 |
| Asset Summary | |||
| Total Current Assets | $155 | $167 | $146 |
| Tangible Fixed Assets | $38 | $37 | $35 |
| Intangible Assets | $71 | $61 | $52 |
| Total Assets | $289 | $281 | $250 |
| Liabilities (mil) | 2023 | 2022 | 2021 |
|---|---|---|---|
| Current Liabilities | |||
| Accounts Payable | $8 | $8 | $6 |
| Short-Term Debt | $ | $ | $ |
| Other Current Liabilities | $19 | $21 | $15 |
| Liability Summary | |||
| Total Current Liabilities | $27 | $29 | $22 |
| Long-Term Debt | $ | $ | $ |
| Other Long-Term Liabilities | $ | $ | $ |
| Total Liabilities | $57 | $56 | $47 |
| Stakeholder's Equity (mil) | 2023 | 2022 | 2021 |
|---|---|---|---|
| Equity | |||
| Common Stock | $14 | $14 | $14 |
| Retained Earnings | $226 | $212 | $192 |
| Equity Summary | |||
| Total Equity | $310 | $300 | $270 |
| Shares Outstanding | 214,128,664 | 216,930,785 | 216,071,141 |